AstraZeneca has concluded the acquisition of the US-based clinical-stage biopharmaceutical company Icosavax in a $1.1bn deal.

The latest development comes after the companies entered a definitive agreement to execute the acquisition in December 2023.

The deal, which was finalised through a tender offer for all outstanding shares at $15 each plus additional contingent value rights, will bolster AstraZeneca’s late-stage pipeline.

Icosavax focuses on the development of differentiated vaccines with greater potential using its protein virus-like particle (VLP) platform.

The company will function as an AstraZeneca subsidiary with its operations in Seattle, US.

AstraZeneca will add IVX-A12, a lead investigational combination protein VLP vaccine candidate of Icosavax, to its vaccines and immune therapies late-stage pipeline.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquisition will strengthen AstraZeneca’s position in the respiratory syncytial virus (RSV) space and is expected to support the progression of IVX-A12, a Phase III-ready vaccine targeting both RSV and human metapneumovirus (hMPV).

RSV and hMPV are significant causes of severe respiratory infections and hospital admissions, particularly among adults aged 60 and above and individuals with chronic ailments.

Phase II trial data showed that IVX-A12 induced strong immune responses against RSV and hMPV a month following vaccination, validating the prior immunogenicity findings from the Phase I trial.

IVX-A12 was also well-tolerated in the Phase II trial demonstrating a safety profile in line with the Phase I study.

It has received fast-track designation from the US Food and Drug Administration (FDA).

The integration of Icosavax’s capabilities in protein design and VLP science into AstraZeneca’s operations will create a platform for developing vaccines against high-burden respiratory conditions.

The FDA previously approved AstraZeneca’s Tagrisso plus chemotherapy for locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor mutations in adults.